Ergomed Notice of Preliminary Results

RNS Number : 9439C

Ergomed plc

28 February 2022

 

 PRESS RELEASE

Notice of Preliminary Results

Guildford, UK - 28 February 2022: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, will announce its preliminary results for the year ending 31 December 2021 on Tuesday 29 March 2022.

Miroslav Reljanović, Executive Chairman, Richard Barfield, Chief Financial Officer, and Keith Byrne, Senior Vice-President, Capital Markets & Strategy, will host an in-person briefing for analysts at 9.30am GMT on the day of the results at the offices of Numis, 45 Gresham St, London EC2V 7BF. There will also be a live webcast and conference call with a Q&A session.

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer) Keith Byrne (Senior Vice-President, Capital Markets & Strategy)
Numis (Nominated Advisor and Joint Broker)	Tel: [phone]
Freddie Barnfield / Euan Brown (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP (Joint Broker) James Steel / Dr Christopher Golden	Tel: [phone]
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Matthew Neal	[e-mail]
Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: http://ergomedplc.com .

 

END

 

 

NOREAEAXAAKAEAA